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OBJECTIVES Implantation of left ventricular assist devices (LVADs) early after acute myocardial infarction
(MI) has traditionally been thought to be associated with high mortality rates due to technical
limitations and severe end-organ dysfunction. At some experienced centers, doctors have
refrained from earlier operation after MI to allow for a period of hemodynamic and end-organ
stabilization.
METHODS We retrospectively investigated the effect of preoperative MI on the survival rates of 25
patients who received a Thermocardiosystems Incorporated LVAD either ,2 weeks (Early)
(n 5 15) or .2 weeks (Late) (n 5 10) after MI. Outcome variables included perioperative
right ventricular assistance (and right-sided circulatory failure), hemodynamic indexes,
percent transplanted or explanted, and mortality.
RESULTS No statistically significant differences were demonstrated between demographic, perioperative
or hemodynamic variables between the Early and Late groups. Patients in the Early group
demonstrated a lower rate of perioperative mechanical right ventricular assistance, but had a
higher rate of perioperative inhaled nitric oxide use. In addition, 67% of patients in the Early
group survived to transplantation and 7% to explantation, findings comparable to those in the
Late group (60% and 0% respectively).
CONCLUSIONS This clinical experience suggests that patients may have comparable outcomes whether
implanted early or late after acute MI. These data therefore support the early identification
and timely application of this modality in post-MI LVAD candidates, as this strategy may
also reveal a subgroup of patients for whom post-MI temporary LVAD insertion may allow
for full ventricular recovery. (J Am Coll Cardiol 1999;33:1903–8) © 1999 by the American
College of Cardiology
Implantation of left ventricular assist devices (LVADs) early
after acute myocardial infarction (MI) has traditionally been
thought to be associated with mortality rates as high as 75%
(1–8). Although initially indicated for both postcardiotomy
shock and failure to wean from cardiopulmonary bypass
(conditions often associated with a preoperative MI),
LVAD insertion after MI has sometimes been delayed at
experienced centers to allow for hemodynamic and end-
organ stabilization before LVAD insertion. Although this
strategy affords the possibility of ventricular recovery with-
out the need for operation, the concomitant risks of ven-
tricular decompensation and the development of malignant
arrhythmias remain high (9).
As experience with the perioperative management of
device recipients has grown, recent interest has focused both
on the prompt implantation of LVADs soon after the
development of cardiogenic shock, as well as on the use of
LVADs as a so-called “bridge to recovery.” With this has
come a renewed emphasis on the timely implantation of
LVADs early after MI to allow for the possible salvage of
viable myocardium that may benefit from temporary ven-
tricular decompression and mechanical circulatory assis-
tance, thereby ultimately allowing for LVAD removal and
full ventricular recovery.
METHODS
Between March 1991 and January 1998, 168 patients
underwent insertion of a Thermocardiosystems (TCI)
(Thermocardiosystems, Woburn, Massachusetts) LVAD at
the Columbia-Presbyterian Medical Center in New York
City. Of this entire cohort, 25 patients had an acute MI less
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than three months before LVAD insertion. Myocardial
infarction was defined by clinical history, serial electrocar-
diographic analysis, cardiac enzymatic evidence (isoenzymes
of creatine phosphokinase) and echocardiography. These
patients were divided on the basis of the interval from MI to
LVAD insertion into cohorts of those who experience a MI
less than two weeks (Early) or great than two weeks (Late)
after MI. Patients with a MI more than three months before
LVAD insertion were excluded from analysis.
Demographic/outcome variables. Demographic variables
analyzed included age, gender, type of LVAD inserted
(pneumatic or vented electric), preoperative assistance with
an intra-aortic balloon pump (IABP) or temporary ventric-
ular assist device, and presenting hemodynamics (central
venous pressure, pulmonary artery pressure, pulmonary
capillary wedge pressure and cardiac output). Perioperative
outcome variables included the need for a right ventricular
assist device (RVAD), the use of perioperative inhaled nitric
oxide and overall perioperative hemodynamics (see above).
Long-term outcome variables included number trans-
planted, number explanted, overall mortality and perioper-
ative complications.
The TCI device. The TCI LVAD is a pusher-plate device
with a maximal stroke volume of approximately 85 cc. It is
implanted through a median sternotomy with the inflow
graft and Teflon sewing cuff inserted into the left ventricular
apex, and the Dacron outflow graft anastomosed to the
ascending aorta after the institution of standard cardiopul-
monary bypass (Fig. 1). The inflow and outflow conduits
have 25-mm porcine valves to ensure unidirectional flow.
The inflow cuff is sewn directly to the left ventricular apex,
after removal of a “core” of apical tissue; in the postinfarc-
tion setting, particular attention is paid to placing large
full-thickness, pledgeted bites in the ventricular myocar-
dium through the infarct zone. The outflow graft is then
anastomosed to the right lateral portion of the ascending
aorta. A properitoneal pocket is created for the device in the
left upper quadrant, before heparinization if possible. The
device itself, when implanted in the left upper quadrant
properitoneal pocket, allows for both the drive line and vent
line also to exit the abdominal wall in the left lower
quadrant.
The device is normally operated in the automatic mode,
which programs ejection when the device is 95% full. The
device may be actuated by a power source that is either
pneumatically or electrically driven.
Statistics. All results were recorded as the mean plus or
minus the standard deviation. Demographic and outcome
variables were compared between the two cohorts by Fischer
exact test for 2 3 2 tables. Statistical significance was
defined as a p value less than 0.05.
RESULTS
Of the 25 patients who had experienced an acute MI before
LVAD insertion, 15 (60%) patients made up the Early
cohort (less than two weeks after MI) and 10 (40%) patients
made up the Late cohort (greater than two weeks after MI).
Four (25%) of the patients in the Early cohort and one
(10%) of the patients in the Late cohort underwent LVAD
insertion in the setting of postcardiotomy cardiogenic shock
after failed coronary artery bypass graft (CABG) revascu-
larization. Where available, peri-MI creatine phosphokinase
values were 2,499.3 6 1,945.5 in the Early cohort, and
1,758.5 6 173.2 in the Late group; q waves on electrocar-
diogram were present in nine (60%) Early and six (60%)
Late patients.
Demographic variables for the two cohorts are displayed
in Table 1. There were no significant differences between
Early and Late cohorts on the basis of initial demographic
profiles. Patients in the Early cohort underwent device
implantation 5.1 6 5.1 days after MI (range 0 to 14 days);
patients in the late cohort underwent device implantation
22.7 6 8.0 days after MI (range 16 to 43 days). Patients in
the Early group more often underwent LVAD insertion in
the setting of postcardiotomy cardiogenic shock after failed
CABG revascularization (26% vs. 10%) when compared
with the Late cohort.
Patients in both cohorts had comparable preoperative
support with IABPs, and two patients in the Early cohort
Abbreviations and Acronyms
CABG 5 coronary artery bypass graft proc
IABP 5 intra-aortic balloon pump
LVAD 5 left ventricular assist device
MI 5 myocardial infarction
MSOF 5 multisystem organ failure
RVAD 5 right ventricular assist device
TCI 5 Thermocardiosystems Incorporated
Figure 1. Illustration demonstrating the implantable Thermocar-
diosystems Incorporated vented electric left ventricular assist de-
vice (LVAD).
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underwent temporary LVAD support with either a
BioMedicus (Medtronics BioMedicus, Eden Prarie, Min-
nesota) or ABIOMED (ABIOMED Cardiovascular, Dan-
vers, Massachusetts) LVAD. Preoperative hemodynamic
profiles were not significantly different between the two
cohorts, as reflected by pulmonary capillary wedge pressure
(28 6 5.0 vs. 29 6 6.0 mm Hg, Early vs. Late) or by cardiac
index (2 6 0.5 vs. 1.8 6 0.4 liters/min/m2, Early vs. Late).
Patients in the Early cohort utilized fewer RVADs in the
perioperative period (7% vs. 20%), but notably were admin-
istered inhaled nitric oxide (30%) more often than patients
in the Late cohort (0%) for perioperative right-sided circu-
latory failure. Patients in the Early cohort were supported
with mechanical left ventricular assistance for a mean of
90.3 6 106.3 days (range 3 to 412 days); those in the Late
cohort were supported for 97.1 6 92.2 days (range 6 to 304
days).
Ventricular tachycardia and ventricular fibrillation af-
flicted four patients in both Early and Late cohorts. One
patient in the Early cohort experienced cardiac arrest pre-
operatively secondary to ventricular fibrillation. The six
other patients all experienced ventricular tachycardia and
ventricular fibrillation in the immediate postoperative pe-
riod after LVAD implantation; in all patients ventricular
fibrillation was ultimately controlled with electrical cardio-
version and medical management while on device support.
Patients were followed until the point of transplantation,
explantation or death; mortality analysis was based on these
Table 1. Patient Demographics in the Early and Late Cohorts
Patient
Age
(yr) LVAD
MI3LVAD
(days)
Preoperative
Assistance Operation
Duration of
Support
(days)
Right
Ventricular
Assistance
Ventricular
Arrhythmia Outcome
1 69 VE 0 IABP LVAD 11 Death (MSOF)
2 59 VE 1 IABP LVAD 15 RVAD/nitric
oxide
Ventricular
fibrillation
Transplant
3 49 VE 1 IABP LVAD 60 Ventricular
fibrillation
Transplant
4 58 VE 1 IABP LVAD Nitric oxide Death (MSOF)
5 53 P 2 IABP LVAD 87 Ventricular
fibrillation
Transplant
6 65 VE 2 IABP LVAD 74 Nitric oxide Transplant
7 55 VE 2 Biomedicus
LVAD
CABG pre-LVAD 128 Nitric oxide Transplant
8 35 VE 2 IABP CABG pre-LVAD 167 Transplant
9 48 VE 4 IABP LVAD 48 Transplant
10 58 VE 5 Abiomed
LVAD
LVAD 4 Nitric oxide Death (MSOF)
11 47 P 8 CABG pre-LVAD 101 Ventricular
fibrillation
Explant
12 52 P 11 IABP CABG/LVAD 3 Death (PE)
13 39 P 12 IABP LVAD 188 Transplant
14 63 VE 13 IABP LVAD 35 Transplant
15 47 VE 14 LVAD 412 Transplant
16 57 P 16 IABP LVAD 304 Death (CVA)
17 58 P 16 IABP CABG/LVAD 54 Ventricular
fibrillation
Transplant
18 54 P 17 IABP LVAD 80 RVAD Death (sepsis)
19 54 VE 19 IABP LVAD 22 Death (graft
dehiscence)
20 60 VE 21 IABP LVAD 126 Transplant
21 63 VE 21 CABG/LVAD 48 Ventricular
fibrillation
Transplant
22 56 P 23 LVAD 6 Death (MSOF)
23 62 VE 25 IABP LVAD 205 RVAD Ventricular
fibrillation
Transplant
24 38 VE 26 LVAD 78 Ventricular
fibrillation
Transplant
25 53 P 43 LVAD 48 Transplant
CABG 5 coronary artery bypass graft; CVA 5 cardiovascular accident; IABP 5 intra-aortic balloon pump; LVAD 5 left ventricular assist device; MI 5 myocardial infarction;
MSOF 5 multisystem organ failure; P 5 pneumatic device; RVAD 5 right ventricular assist device; VE 5 vented electric device.
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three censor criteria. The leading cause of death in both
cohorts was multisystem organ failure (MSOF), most often
related to sepsis. One patient in the early group died of
MSOF four days after LVAD insertion, and another died of
a pulmonary embolus three days after LVAD insertion. One
additional patient in the Early group, who underwent a
CABG procedure one day after MI, and an LVAD implan-
tation seven days later, was successfully weaned from device
support and underwent device removal 101 days after device
support. At 24 months after explantation, he was noted to
have a 50% estimated ejection fraction by nuclear ventricu-
lography multigated acquisition scan; the patient ultimately
died of a presumed (unwitnessed) fatal arrhythmia approx-
imately 26 months after his LVAD removal.
DISCUSSION
Despite advances in the timely medical management of the
syndrome and its sequelae, cardiogenic shock associated
with acute MI remains a diagnosis associated with a
mortality rate between 65% and 80% (10). In addition, the
use of IABP counterpulsation as a temporizing measure
while awaiting ventricular recovery continues to have a 30%
to 75% mortality rate in the setting of acute MI, an outcome
comparable to that associated with medical therapy alone
(11–13). Although the success of both LVAD support for
postcardiotomy cardiogenic shock and LVADs as a bridge
to transplantation has been well established, their use for
post-MI cardiogenic shock, either postcardiotomy or after
medical management has failed, remains to be defined fully
(14).
Since the first description of mechanical left ventricular
assistance for acute MI in 1957, the application of LVADs
and biventricular assist devices for this indication has
continued to expand despite variable results (1–8). Early
experience with LVAD insertion for acute MI revealed
survival rates between 10% and 60%, a finding that discour-
aged the early application of mechanical ventricular assis-
tance for this indication. However, later studies document-
ing both the beneficial influence of ventricular assistance on
end-organ function, as well as the possibility of ventricular
decompression allowing for full or partial myocardial recov-
ery have led investigators to revisit the notion of early
LVAD insertion for acute MI (15).
Experienced centers have sometimes refrained from ear-
lier operation in this setting to allow for hemodynamic and
end-organ stabilization before LVAD insertion. For these
potential assist device recipients, the concomitant risks of
infarction extension and malignant arrhythmia must be
weighed carefully against those of the operation itself.
Although in the early years of device support these risks
were comparable, recent improvement in survival statistics
for LVAD implantation has rendered the risks of the
operation considerably less. Ventricular decompression and
the restoration of blood flow to the myocardium have been
demonstrated to limit infarct size and expansion, a finding
supportive of early LVAD insertion not only as a bridge to
transplantation, but also as a bridge to recovery (16,17). In
addition, the development of malignant arrhythmias due to
infarction extension may be exacerbated further by medical
management itself (which may also reduce ventricular func-
tion), and we and others have described successful long-
term LVAD support for patients with active ventricular
arrhythmias (17–20).
Several advances in surgical implant technique have also
substantially improved LVAD recipient survival postinfarc-
tion. We have in recent years placed importance during
implantation on the use of pericardial pledgeted sutures for
the inflow cannula, with particular emphasis on the use of
large, full-thickness bites of ventricular myocardium
through the infarct zone. The short inflow cannula of the
TCI device used is also advantageous in such patients, in
that its shorter, wider inflow substantially reduces the
residual left ventricular pressure, ultimately leading to fewer
bleeding complications. Finally, our increasing use of ther-
apeutic adjuncts, including inhaled nitric oxide and low dose
intravenous arginine vasopressin, has undoubtedly dramat-
ically improved the morbidity of this difficult patient pop-
ulation (21,22).
Our experience described herein is notable for a series of
observations. First, patients in the Early cohort had a
substantially decreased mortality (26%) when compared
with those in the Late cohort (40%) (p . 0.05). Patients
were more likely to have had an LVAD implanted early
after acute MI in recent years, owing to a programmatic
change in our sensibility over time; this change is reflected
in the greater proportion of more recent vented electric
LVADs implanted in the Early group. Although this
tendency may, to some extent, have biased the data de-
scribed, both groups notably comprised patients distributed
throughout the time period studied. Furthermore, the
overall survival rate to transplantation or explantation in the
Early cohort (74%) is comparable to that described by us in
previous reviews of our experience with the electric TCI
LVAD, suggesting that this cohort of patients with isch-
emic cardiomyopathy is not at a significant survival disad-
vantage owing to the etiology of their heart failure (22).
Second, right-sided circulatory failure (defined as the
need for either an RVAD, or the use of inhaled nitric oxide)
remains a substantial source of morbidity for acute MI
patients in the immediate post-LVAD setting, afflicting
nearly one third of patients in both cohorts combined. The
Early cohort enjoyed an increased use of nitric oxide (30%),
and decreased use of RVADs (7%), when compared with
the Late cohort (0% and 20% respectively), a fact that again
likely reflects their more recent dates of implantation. We
have previously reported the efficacy of inhaled nitric oxide
in LVAD recipients for perioperative right-sided circulatory
failure, and have noted a substantial decrease in our insti-
tutional use of RVADs as a result (23,24). The trends we
report herein also parallel previous data reported from our
institutional experience with the TCI device in 1990
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through 1997, in which 27% of an overall cohort of 85
patients experienced intraoperative right-sided circulatory
failure; 4/16 pneumatic device recipients, and 2/8 electric
device recipients required RVAD insertion (compared with
3/16 and 6/8 requiring nitric oxide therapy respectively)
(22). Moreover, these data refute the notion that biventricu-
lar failure may account for the discrepancy in survival
between cohorts, as the overall use of therapeutic adjuncts
for right-sided circulatory failure was in fact higher in the
Early group.
Third, we demonstrated a 30% to 40% rate of malignant
ventricular arrhythmias that developed within both cohorts
(one of which accounted for a preoperative cardiac arrest in
a patient in the Early group), suggesting that the risk of this
occurrence in the perioperative period for LVAD patients
after acute MI remains substantial. This finding is consis-
tent with other published reports that document an inci-
dence of post-MI ventricular tachyarrhythmias of as high as
65% (9). All patients who experienced ventricular fibrilla-
tion perioperatively underwent electrical cardioversion and
subsequent medical management with antiarrhythmic med-
ications. These patients tolerated their ventricular arrhyth-
mias, and all eight patients survived to transplantation or
explantation of their device.
Finally, the primary cause of death in the Early cohort
was MSOF, most often due to overwhelming sepsis. It
remains controvertible whether early implantation may not
allow for scrutiny of all potential negative determinants of
post-LVAD outcome (e.g., infection), as has been sug-
gested by others (24). Arguably, those with “long-standing”
(.2 weeks) ischemic cardiomyopathy should be at an
increased risk of infectious and end-organ postoperative
complications owing to prolonged hypoperfusion and in-
hospital associated risks; however, these observations re-
quire a large prospective randomized analysis for confirma-
tion.
Limitations. Several limitations are important to note with
regard to these data. First, these results represent the
findings of a retrospective clinical experience, rather than a
prospective randomized trial. Second, although unexpect-
edly favorable outcomes are described for patients implanted
early after MI, undoubtedly certain outcomes (e.g., the rate
of survival to transplantation) may have been tempered in
part both by the patients’ clinical status, as well as by the
prevailing practice patterns in transplantation; these results
must therefore must be viewed with caution. Despite this,
the inherent characteristics of a presumably sicker cohort
(those early after MI) should have biased these data against
describing comparable outcome results; the lack of appre-
ciable differences in preoperative characteristics in both
cohorts argues against egregious differences in patient se-
lection. The selection criteria (LVAD “screening scale”) on
which we have based our decision for implantation have
been described previously (25). Clearly, the time interval
since a prior MI, although an important factor, is but one of
many contributing demographic characteristics affecting
overall outcome. Although these data do not promote the
implantation of LVADs early after MI for all patients, they
do suggest its feasibility and furthermore refute its position
as either an absolute or relative contraindication.
Conclusions. These data support the early implantation of
LVADs for acute myocardial infarction either postcar-
diotomy, or in the setting of decompensation despite
maximal medical management. The comparable rates of
survival to transplantation or explantation refute the notion
of a two-week “recovery period,” particularly in light of
recent trends toward the use of mechanical ventricular
assistance for myocardial recovery. Many of the patients in
the Early cohort while receiving temporary IABP support
were transferred to our institution for either LVAD inser-
tion, or for weaning from IABP. We contend that for these
patients, the aggressive implantation of IABPs or temporary
assist devices—and the rapid referral to tertiary care centers
for more long-term mechanical support—will allow for a
greater percentage of patients who may be weaned com-
pletely after intermediate-term LVAD support, end-organ
and hemodynamic stabilization, and partial or full ventric-
ular recovery. Taken together, these findings support the
notion of a seamless “bridge to recovery” program in which
smaller hospitals with temporary device programs may refer
patients (such as those who undergo temporary device
insertion early after acute MI) to larger centers for longer
term device support as a bridge to transplantation, destina-
tion or recovery.
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